Novan Selected to Present at Inaugural Dermatology Summit

Durham, NC (December 12, 2013) – Novan Therapeutics announced today that the Company has been selected to present at the inaugural Dermatology Summit in San Francisco on January 12, 2014.  The Dermatology Summit precedes the JP Morgan Healthcare Conference and brings together leading dermatology companies, financial institutions, and promising technologies to advance innovation in dermatology.   Dr. Nathan Stasko, Novan’s President, is scheduled to speak during the Entrepreneurial Company Showcase.

  • Sunday, January 12, 2014, 1:00 - 6:00 PM
  • Mission Bay Conference Center, 1675 Owens Street, San Francisco, CA

William Ju, M.D., President and a trustee of Advancing Innovation in Dermatology, Inc., stated “At this Inaugural Dermatology Summit we look forward to the ideas, technologies, and platforms discussed at this unique forum becoming the foundation for the next generation of dermatology products.  As such, we are delighted that Novan Therapeutics will be presenting at the Entrepreneurial Company Showcase.”

 Novan will also be presenting at the sixth annual Biotech Showcase investor and partnering conference that runs concurrently with the JP Morgan Healthcare Conference in San Francisco.   Co-produced annually by Demy-Colton Life Science Advisors and EBD Group, the 2014 showcase will be held at the Parc 55 Wyndham San Francisco - Union Square.

  • Monday, January 13, 2014, 4:00 PM
  • Track B – Mission I (4th Floor)

About Advancing Innovations in Dermatology, Inc.

Advancing Innovation in Dermatology (AID) works to facilitate meaningful and productive interactions and to help create bridges among a broad range of constituencies.  These stakeholders share a common interest in bringing to market an increased number of innovative products that substantially improve dermatologic health. 

About Novan, Inc.

Novan Therapeutics is a clinical-stage specialty pharmaceutical company bringing the power of nitric oxide to dermatology and wound care.  Novan’s core technologies solve the previous delivery issues with nitric oxide by storing the gaseous species on macromolecules that result in a diverse pipeline of “timed-release” nitric oxide-releasing new chemical entities.  Novan is currently developing a range of nitric oxide-releasing drug products including topical gels, creams, ointments, and wound dressings which can be tailored to treat specific skin conditions.


Julia Brannan, Pascale Communications, LLC, on behalf of Novan Therapeutics

Back to Press Releases